Profile: Arena Pharmaceuticals Inc (ARNA.A)
24 Jun 2016
Arena Pharmaceuticals, Inc., incorporated on April 14, 1997, is a biopharmaceutical company focused on discovering, developing and commercializing small molecule drugs that target G protein-coupled receptors (GPCRs). The Company's drug, Lorcaserin, is approved for marketing in the United States and South Korea for the indication of weight management. The Company's drug candidates in clinical development include APD334 for autoimmune diseases, ralinepag for vascular diseases and APD371 for pain. The Company's programs under collaboration include nelotanserin for dementia-associated psychosis, temanogrel for thrombotic diseases, and an undisclosed orphan GPCR for central nervous system (CNS) indication(s).
The Company's lorcaserin is being commercialized under the brand name, BELVIQ BELVIQ is indicated in the United States and South Korea as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adult patients with an initial body mass index (BMI) of approximately 30 kilograms/square meters or greater (obese), or over 27 kilograms/square meters or greater (overweight) in the presence of a weight-related comorbid condition. The recommended daily dose of BELVIQ is approximately 10 milligrams twice daily. The Company is developing a once-daily formulation of lorcaserin for use for weight management, which is planned to be marketed under the brand name, BELVIQ XR.
APD334, an orally available modulator of the sphingosine 1-phosphate subtype 1 (S1P1) receptor, is the Company's internally discovered investigational drug candidate intended for the treatment of a number of autoimmune diseases, such as multiple sclerosis, psoriasis, inflammatory bowel diseases and rheumatoid arthritis. The Company has commenced the Phase Ib multiple-ascending dose clinical trial for APD334.
Ralinepag, an orally available agonist of the prostacyclin receptor, is the Company's internally discovered investigational drug candidate intended for the treatment of pulmonary arterial hypertension (PAH). The Company has initiated patient dosing in approximately 20 weeks, randomized, double-blind and placebo-controlled Phase II clinical trial of ralinepag.
APD371, an orally available agonist of the cannabinoid-2 (CB2) receptor, is an internally discovered investigational drug candidate the Company is exploring for the treatment of pain. The Company has initiated a Phase I multiple-ascending dose trial of APD371.
Nelotanserin, an orally available inverse agonist of the serotonin 2A receptor, is an internally discovered investigational drug candidate that the Company studied for sleep maintenance. The Company under the collaboration with Axovant Sciences Ltd. (Axovant), initiated a Phase II clinical trial for nelotanserin in patients with dementia with Lewy Bodies, which includes Lewy Body and Parkinson's disease dementia, suffering from visual hallucinations.
Temanogrel, an orally available inverse agonist of the serotonin 2A receptor, is an internally discovered investigational drug candidate intended for the treatment of thrombotic diseases. The Company granted Ildong exclusive rights to commercialize temanogrel in South Korea for myocardial infarction, acute coronary syndrome, stroke, peripheral artery disease and other cardiovascular diseases.
Orphan GPCR Program
The Company has entered into an agreement with Boehringer Ingelheim International GmbH to conduct joint research to identify drug candidates targeting a GPCR that belongs to the group of orphan CNS receptors. The agreement grants Boehringer Ingelheim around the world rights to develop, manufacture and commercialize products resulting from the collaboration.
The Company competes with Roche Group, GlaxoSmithKline Consumer Healthcare, VIVUS Inc., Orexigen Therapeutics, Inc. and Novo Nordisk.
Arena Pharmaceuticals Inc
6154 Nancy Ridge Dr
SAN DIEGO CA 92121-3223
Company Web Links
- BRIEF-Arena Pharmaceuticals Inc announces appointment of Kevin Lind as CFO
- BRIEF-Arena Pharmaceuticals files for mixed shelf of up to $250 mln
- BRIEF-Arena Pharmaceuticals names Amit Munshi CEO
- BRIEF-Arena Pharmaceuticals Q1 loss per share $0.09
- BRIEF-Arena Pharmaceuticals reports favorable results from Phase 1B clinical trial of APD371